Summary by Moomoo AI
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has successfully addressed a listing deficiency with The Nasdaq Stock Market. The company was previously notified by Nasdaq on September 1, 2023, that it did not meet the minimum Market Value of Publicly Held Shares (MVPHS) of $5,000,000 required for continued listing on the Nasdaq Global Market. However, ZyVersa Therapeutics received approval on February 29, 2024, to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effectively curing the MVPHS deficiency. The transfer became effective on March 1, 2024, with the company's common stock continuing to trade under the ticker symbol 'ZVSA'. The Nasdaq Capital Market has similar operational characteristics to the Nasdaq Global Market, but with different financial requirements. As of the transfer date, ZyVersa Therapeutics reported having 7,583,863 shares of common stock outstanding.